HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Nasopharyngeal Diseases

Subscribe to New Research on Nasopharyngeal Diseases

Pathological processes involving the NASOPHARYNX.

Also Known As:

Diseases of Nasopharynx; Disease, Nasopharyngeal; Diseases, Nasopharyngeal; Nasopharyngeal Disease; Nasopharynx Disease; Nasopharynx Diseases

Networked: 9 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Disease Context: Research Results

Stomatognathic Diseases: 372
- Pharyngeal Diseases: 11
  - Nasopharyngeal Diseases: 9
    - Nasopharyngeal Neoplasms: 591
    - Nasopharyngitis: 192
Otorhinolaryngologic Diseases: 130
- Pharyngeal Diseases: 11
  - Nasopharyngeal Diseases: 9
    - Nasopharyngeal Neoplasms: 591
    - Nasopharyngitis: 192

Related Diseases

1.	Otitis Media
2.	Oropharyngeal Neoplasms
3.	Neoplasms (Cancer)
4.	Infectious Mononucleosis (Glandular Fever)
5.	Hodgkin Disease (Hodgkin's Disease)

Experts

1.	Faber, Tina E: 1 article (07/2012)
2.	Groen, Henk: 1 article (07/2012)
3.	Bont, Louis J: 1 article (07/2012)
4.	Welfing, Martine: 1 article (07/2012)
5.	Jansen, Koos J G: 1 article (07/2012)
6.	Forastiere, Arlene A: 1 article (06/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Nasopharyngeal Diseases:

1.	heptavalent pneumococcal conjugate vaccine (Prevnar)IBA 04/01/1998 - "Studies to assess vaccine efficacy of PNCRM7 for prevention of systemic disease, nasopharyngeal colonization, and acute otitis media are in progress. "
2.	Cisplatin (Platino)FDA LinkGeneric 06/15/2008 - "Concomitant cisplatin-based chemotherapy and radiotherapy is the strategy that has proven most effective for organ preservation for larynx and oropharynx cancers, the treatment of unresectable disease, nasopharyngeal cancer and the post-operative adjuvant treatment of patients at high risk of recurrence. "
3.	AntigensIBA 01/01/1990 - "It is highly sensitive, specific, and effective: it detected adenovirus antigens in 15 percent of 196 patients with acute respiratory diseases (nasopharyngeal washings and aspirates were under study)."
4.	ChemokinesIBA 07/01/2012 - "During course of disease, nasopharyngeal concentrations of most cytokines and chemokines decreased, reaching statistical significance for IL-6 and IP-10. "
5.	CytokinesIBA 07/01/2012 - "During course of disease, nasopharyngeal concentrations of most cytokines and chemokines decreased, reaching statistical significance for IL-6 and IP-10. "
6.	Interleukin-6 (Interleukin 6)IBA 07/01/2012 - "During course of disease, nasopharyngeal concentrations of most cytokines and chemokines decreased, reaching statistical significance for IL-6 and IP-10. "
7.	RadiumIBA 07/09/1950 - "[Treatment of certain nasopharyngeal diseases with the radium emanator]."
8.	BismuthIBA 03/01/1957 - "[Treatment & prevention of acute nasopharyngeal diseases in a communal environment; a new oral bismuth derivative]."
9.	Nasopharyngeal carcinomaIBA 03/01/1999 - "The initial nasopharyngeal disease for which radiotherapy was indicated was nasopharyngeal carcinoma (six patients) and nasopharyngeal lymphoma (one patient). "

Therapies and Procedures

1.	Radiotherapy 03/01/1980 - "Principles of radiotherapy are expounded and a more diligent search for detecting nasopharyngeal disease is proposed." 03/01/1999 - "The initial nasopharyngeal disease for which radiotherapy was indicated was nasopharyngeal carcinoma (six patients) and nasopharyngeal lymphoma (one patient). " 06/15/2008 - "Concomitant cisplatin-based chemotherapy and radiotherapy is the strategy that has proven most effective for organ preservation for larynx and oropharynx cancers, the treatment of unresectable disease, nasopharyngeal cancer and the post-operative adjuvant treatment of patients at high risk of recurrence. "
2.	Drug Therapy (Chemotherapy) 06/15/2008 - "Concomitant cisplatin-based chemotherapy and radiotherapy is the strategy that has proven most effective for organ preservation for larynx and oropharynx cancers, the treatment of unresectable disease, nasopharyngeal cancer and the post-operative adjuvant treatment of patients at high risk of recurrence. "
3.	Transplants (Transplant) 08/01/1999 - "It would seem reasonable to suggest that emerging technologies are at a level where vaccine trials aimed at controlling infectious mononucleosis, post-transplant lymphoproliferative disease, nasopharyngeal carcinoma and Hodgkin's disease are justified. "